Delta Med Group and Pentaferte announce a strategic partnership to compete in the European infusion medical device market.
Delta Med Group and Pentaferte, among the leaders in the infusion medical device segment, announce a strategic partnership to create a champion in the Italian and European market.
Delta Med is a leading Italian company specialized in vascular access devices for oncology and analgesic therapies. White Bridge Investments, the Group’s controlling shareholder, invested in Delta Med to create a platform in the medical device space.
Pentaferte is specialised in the production and distribution of infusion therapy syringes, pre-filled syringes and infusion pumps.
This partnership is part of a larger project aiming at creating a European leader in medical devices for the hospital and home therapy sectors through the aggregation of companies that are leaders in their niches. In August, Delta Med acquired Adria Med, a leading company in elastomeric infusion pumps.
Pentaferte’s main shareholders – the Romagnoli family and some key managers – will hold a relevant stake in the new Group. Gianluca Romagnoli, who has led Pentaferte over the past few years, will keep a key role in the Pentaferte in the next phase of growth.
Gianluca Romagnoli, President of the Pentaferte Group commented, “The partnership with Delta Med represents a milestone in Pentaferte’s growth. This transaction will allow us to accelerate our expansion strategy in Italy and Europe, investing in the best talents and maintaining the high- quality standards we offer to our clients. Our roles and direct involvement in the Group as shareholders and managers are a proof of our commitment and trust in the growth potential of the Group that aims at becoming an Italian and European leader in infusion systems“.
Gabriele Giovanelli, CEO of Delta Med, added, “Pentaferte is well-recognized in Italy and France for the development of medical devices for hospitals and home care therapies. The partnership with Pentaferte represents another key step in our aggregation project toward the creation of a European leader focused on infusion systems.”
In the transaction, Delta Med was assisted by the law firm White&Case as legal advisor, with partners Leonardo Graffi and Alessandro Seganfreddo and associates Nicolò Miglio and Ioana Gaga. Michele Aprile, Paolo Ludovici and Roger Demoro, representing Gatti Pavesi Bianchi Ludovici, were in charge of the Italian tax aspects, while Michel-Ange of the French tax aspects. Deloitte was responsible for the financial and tax due diligence, with a team led by Marco Bastasin for financial aspects and Mario De Blasi for the tax ones. Pentaferte and its shareholders were supported by the law firm Gianni & Orrigoni as legal advisor, with Partner Federico Dettori, Managing Associate Matteo Canonico and Associate Arianna Paone. The law firm Fidal, with a team coordinated by Giovanna Figuccio, assisted Pentaferte and its shareholders for French legal and tax aspects, while the Partner Gianluca Settepani and Luciano Volta of Studio Gnudi were in charge of the financial and tax aspects.